Polarean Imaging Plc
("Polarean" or the "Company")
Block Listing Six Monthly Return
Polarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in advanced MRI scanning of the lungs, today makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:
| Name of applicant: | Polarean Imaging Plc | ||||
| Name of scheme: | Polarean Share Option Plan | ||||
| Number and class of securities originally admitted: | 8,000,000 ordinary shares of £0.00037 each | ||||
| Date of admission: | 29 July 2021 | ||||
| Period of return: | From: | 27 July 2023 | To: | 26 January 2024 | |
| Balance of unallotted securities under scheme(s) from previous return: | 3,172,835 | ||||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 0
| ||||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 1,948,262
| ||||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 1,224,573 | ||||
| Total number of securities in issue at the end of the period | 215,848,593 | ||||
| | | | | | |
| Name of contact: | Charles F. Osborne, Jr., Chief Financial Officer |
| Telephone number of contact: | + 44 (0)20 7933 8780 or polarean@walbrookpr.com |
Enquiries:
| Polarean Imaging plc | |||||
| Christopher von Jako, Chief Executive Officer | Via Walbrook PR | ||||
| Charles Osborne, Chief Financial Officer |
| ||||
| |
| ||||
| Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker) | +44 (0)20 7710 7600 | ||||
| Nicholas Moore / Samira Essebiyea / Kate Hanshaw (Healthcare Investment Banking) | | ||||
| Nick Adams / Nick Harland (Corporate Broking) | |||||
| | | ||||
| Walbrook PR | Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com | ||||
| Anna Dunphy /Phillip Marriage | Mob: +44 (0)7876 741 001 / +44 (0) 7867 984 082 | ||||
About Polarean (www.polarean.com)
The Company and its wholly-owned U.S. subsidiary, Polarean, Inc. are revenue-generating, medical imaging technology companies. The Company aspires to revolutionise pulmonary medicine by bringing the power and safety of MRI to the respiratory healthcare community which is desperately in need of new modern solutions to evaluate lung function. Polarean is dedicated to researching, developing, and commercialising these novel imaging solutions with their non-invasive and radiation-free functional MRI platform. The Company strives to address the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI contrast agent (XENOVIEW?) to be FDA-approved in the United States. The Company also commercialises the systems, software, and accessories to support fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit www.polarean.com.
PLC-RNS-2327
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.